CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Capricor Therapeutics, Inc.

CAPR
$514MSmall Cap

Next catalyst

PDUFANov 22, 2026in 5 days

Deramiocel (CAP-1002)

Duchenne muscular dystrophy (upper limb function)

Get an email about CAPR's next catalysts

Track Capricor Therapeutics (CAPR) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

No other upcoming event in our data.

Catalyst Timeline

1 upcoming, 1 past

PDUFANext

FDA PDUFA Date Deramiocel

Nov 22, 2026Deramiocel (CAP-1002)

For Duchenne muscular dystrophy (upper limb function). BLA; extended from Aug 22 after a major amendment. Verified against the company announcement on 2026-10-16.

Source

Upcoming FDA decisions

How CAPR's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical PreparationsπŸ‡ΊπŸ‡ΈNorth AmericaSAN DIEGO160 employees
Website

Frequently asked questions

What is in Capricor Therapeutics, Inc.'s drug pipeline?β†’

CatalystAlert tracks 6 drug candidates in Capricor Therapeutics, Inc.'s (CAPR) pipeline across Phase 3, Phase 2. Its lead program is Deramiocel (CAP-1002) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Capricor Therapeutics, Inc.'s next FDA catalyst?β†’

Capricor Therapeutics, Inc.'s (CAPR) next tracked catalyst is a PDUFA date expected Nov 22, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track CAPR biotech catalysts?β†’

Add CAPR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Capricor Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply